GlassScriptPhysician profile
Harry Tg Chingon
NPI 1942242854
$15,327.04
in general payments reported to CMS, 2019-2025
19 companies · $2,414 in 2025
The $2,414 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,620 · 2020: $1,989 · 2021: $2,044 · 2022: $2,297 · 2023: $2,305 · 2024: $2,658 · 2025: $2,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,376.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $2,498.81 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,450.97 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,499.29 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,496.80 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,441.93 | 2021-2025 | Vraylar |
| Alkermes, INC. | $1,267.22 | 2022-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $1,222.35 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $773.52 | 2019-2025 | Ingrezza |
| Allergan, INC. | $507.38 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $430.78 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $426.65 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Indivior INC. | $411.37 | 2022-2024 | Perseris |
| Axsome Therapeutics, INC. | $275.39 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $249.58 | 2025 | Fanapt |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $133.01 | 2024-2025 | Rexulti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $90.55 | 2023-2025 | Uzedy, Austedo Xr |
| Eisai INC. | $72.21 | 2020 | |
| Avanir Pharmaceuticals, INC. | $54.96 | 2022 | |
| Acadia Pharmaceuticals INC | $24.27 | 2024 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Chingon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.